Solace Health has secured $130 million in Series C financing, bringing its valuation to more than $1 billion and positioning the company as a new entrant into unicorn status. The round was led by IVP, with participation from Menlo Ventures, SignalFire, Torch Capital, Inspired Capital and RiverPark Ventures.
The California-based company operates a healthcare navigation platform that connects patients with expert advocates via phone, text or email. These advocates support individuals through a range of healthcare needs, including managing new diagnoses, identifying appropriate physicians, coordinating care, securing insurance approvals and navigating chronic conditions.
Solace’s services are covered by Medicare, most Medicare Advantage plans and select commercial insurance carriers. In addition to direct patient engagement, the company enables providers to refer patients to its advocacy network. Solace also offers a proprietary electronic health record system that allows advocates to access and update patient medical records to streamline coordination and navigation.
The newly raised capital will be used to expand Solace’s network of advocates serving Medicare and Medicare Advantage members, enhance its technology platform and support clinical research initiatives. The company has also indicated plans to broaden partnerships with payers and providers, with a focus on embedding advocacy earlier in the patient care journey.
Commenting on the investment, Jeremy Gurewitz, CEO and cofounder of Solace, said, “IVP understands how to scale companies where execution and consequences are inseparable," Jeremy Gurewitz, CEO and cofounder of Solace, said in a statement. "This partnership allows us to embed advocacy earlier in care, at national scale, and establish it as a permanent part of how healthcare works in the United States.
The Series C follows a $60 million Series B round completed in 2025 and a $14 million Series A raise in 2024, reflecting sustained investor interest in patient advocacy and navigation models.
Within the broader market, Citizen Health represents another company focused on patient advocacy, particularly for rare disease populations. Citizen Health raised $30 million in Series A funding last year, bringing its total funding to $44 million since launching in 2023, following a $14.5 million seed round in 2024.
Click here for the original news story.